CNTA earnings analysis
What we found in CNTA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Centessa Pharmaceuticals reported a challenging first quarter of 2026, with revenue dropping to $0 million from $15 million in Q1 2025, coupled with a significant increase in losses due to rising R&D expenditures. Total operating expenses surged by 47.7% to $79.8 million, leading to a net loss of $79.2 million compared to a loss of $26.1 million in the prior year. Additionally, the company's cash reserves stood at $533.7 million, projected to sustain operations until mid-2028 despite ongoing substantial expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Drops to $0 Million
- Centessa's revenue fell to $0 million in Q1 2026 from $15 million in Q1 2025, reflecting a major decline.
- Net Loss Widens to $79.2 Million
- The net loss increased to $79.2 million in Q1 2026, compared to a loss of $26.1 million in the prior year.
- Increase in Operating Expenses
- Operating expenses rose by 47.7% to $79.8 million primarily due to increased R&D costs.
- Cash Reserves at $533.7 Million
- As of March 31, 2026, Centessa had cash reserves of $533.7 million, funding operations into mid-2028.
- R&D Expenses Spike by 79.31%
- R&D expenses increased from $33.4 million in Q1 2025 to $59.9 million in Q1 2026, due to higher clinical costs.
- Interest Income Declines
- Interest and investment income fell 31.7% to $5.1 million compared to $7.9 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Losses
- Operating loss rose to $79.8 million in Q1 2026 from $30.8 million in Q1 2025, reflecting escalating costs.
- Dependence on Third-Party Manufacturers
- Reliance on third-party manufacturers exposes Centessa to risks of disruptions impacting product availability.
- Reputation Risks from Cyber Threats
- Past security incidents raise concerns over potential future breaches affecting operations and proprietary information.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.48
What they said about what is next.
Management reiterated the expectation that cash reserves will fund operations into mid-2028 with ongoing significant operational losses.
The filing reads worse than the one before it.
What came before.
- 10-K · March 31, 2026
- Centessa describes a focused "pipeline-in-a-pathway" strategy to lead orexin-based neuroscience with a franchise of OX2R agonists lead by cleminorexton (late-stage). The company announced a Transaction Agreement on…
- 10-Q · November 12, 2024
- Centessa reported a Q3 net loss of $42,566 (three months ended September 30, 2024) or $(0.37) per share, with loss from operations of $46,405 versus $40,209 in the prior-year quarter (worsening by $6,196). Liquidity…
- 10-Q · May 13, 2024
- Centessa reported a net loss of $38,046,000 (‑$0.38 per share) for the three months ended March 31, 2024, an improvement versus a $50,714,000 loss (‑$0.53 per share) in the prior year period. Cash and short-term…
- 10-K · March 28, 2024
- Centessa is a clinical-stage biopharma focused on advancing a portfolio of high-conviction programs (SerpinPC for hemophilia, ORX750 OX2R agonist, LB101 LockBody) toward registrational studies and early clinical…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CNTA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever